252 related articles for article (PubMed ID: 32179677)
21. Investigation of Siderophore-Platinum(IV) Conjugates Reveals Differing Antibacterial Activity and DNA Damage Depending on the Platinum Cargo.
Guo C; Wang KA; Nolan EM
ACS Infect Dis; 2024 Apr; 10(4):1250-1266. PubMed ID: 38436588
[TBL] [Abstract][Full Text] [Related]
22. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo.
Xiao H; Noble GT; Stefanick JF; Qi R; Kiziltepe T; Jing X; Bilgicer B
J Control Release; 2014 Jan; 173():11-7. PubMed ID: 24511610
[TBL] [Abstract][Full Text] [Related]
23. Photoinduced reduction of Pt(IV) within an anti-proliferative Pt(IV)-texaphyrin conjugate.
Thiabaud G; Arambula JF; Siddik ZH; Sessler JL
Chemistry; 2014 Jul; 20(29):8942-7. PubMed ID: 24961491
[TBL] [Abstract][Full Text] [Related]
24. Fighting against drug-resistant tumors by the inhibition of γ-glutamyl transferase with supramolecular platinum prodrug nano-assemblies.
Wang L; Liu Z; He S; He S; Wang Y
J Mater Chem B; 2021 Jun; 9(22):4587-4595. PubMed ID: 34059856
[TBL] [Abstract][Full Text] [Related]
25. Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups.
Zhou Q; Chen S; Xu Z; Liu G; Zhang S; Wang Z; Tse MK; Yiu SM; Zhu G
Angew Chem Int Ed Engl; 2023 Apr; 62(18):e202302156. PubMed ID: 36878864
[TBL] [Abstract][Full Text] [Related]
26. Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.
Chen SJ; Kuo CC; Pan HY; Tsou TC; Yeh SC; Chang JY
Biochem Pharmacol; 2015 May; 95(1):28-37. PubMed ID: 25801007
[TBL] [Abstract][Full Text] [Related]
27. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
28. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
29. Mono-functionalized glycosylated platinum(IV) complexes possessed both pH and redox dual-responsive properties: Exhibited enhanced safety and preferentially accumulated in cancer cells in vitro and in vivo.
Ma J; Yang X; Hao W; Huang Z; Wang X; Wang PG
Eur J Med Chem; 2017 Mar; 128():45-55. PubMed ID: 28147308
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
Svensson HP; Frank IS; Berry KK; Senter PD
J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
[TBL] [Abstract][Full Text] [Related]
31. Glycosylated platinum(iv) prodrugs demonstrated significant therapeutic efficacy in cancer cells and minimized side-effects.
Ma J; Wang Q; Yang X; Hao W; Huang Z; Zhang J; Wang X; Wang PG
Dalton Trans; 2016 Jul; 45(29):11830-8. PubMed ID: 27373800
[TBL] [Abstract][Full Text] [Related]
32. GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates.
Liu R; Fu Z; Zhao M; Gao X; Li H; Mi Q; Liu P; Yang J; Yao Z; Gao Q
Oncotarget; 2017 Jun; 8(24):39476-39496. PubMed ID: 28467806
[TBL] [Abstract][Full Text] [Related]
33. Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery.
Matha K; Lollo G; Taurino G; Respaud R; Marigo I; Shariati M; Bussolati O; Vermeulen A; Remaut K; Benoit JP
Eur J Pharm Biopharm; 2020 May; 150():1-13. PubMed ID: 32113915
[TBL] [Abstract][Full Text] [Related]
34. Conjugation of oxaliplatin with PEGylated-nanobody for enhancing tumor targeting and prolonging circulation.
Li L; Zhu Y; Liu M; Jin D; Zhang L; Cheng J; Liu Y
J Inorg Biochem; 2021 Oct; 223():111553. PubMed ID: 34340059
[TBL] [Abstract][Full Text] [Related]
35. A Pt(IV)-based mononitro-naphthalimide conjugate with minimized side-effects targeting DNA damage response via a dual-DNA-damage approach to overcome cisplatin resistance.
Li Y; Yue K; Li L; Niu J; Liu H; Ma J; Xie S
Bioorg Chem; 2020 Aug; 101():104011. PubMed ID: 32599363
[TBL] [Abstract][Full Text] [Related]
36. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
37. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.
Yao H; Chen S; Deng Z; Tse MK; Matsuda Y; Zhu G
Inorg Chem; 2020 Aug; 59(16):11823-11833. PubMed ID: 32799491
[TBL] [Abstract][Full Text] [Related]
38. Intracellular glutathione-depleting polymeric micelles for cisplatin prodrug delivery to overcome cisplatin resistance of cancers.
Han Y; Yin W; Li J; Zhao H; Zha Z; Ke W; Wang Y; He C; Ge Z
J Control Release; 2018 Mar; 273():30-39. PubMed ID: 29371047
[TBL] [Abstract][Full Text] [Related]
39. Galactose conjugated platinum(II) complex targeting the Warburg effect for treatment of non-small cell lung cancer and colon cancer.
Wu M; Li H; Liu R; Gao X; Zhang M; Liu P; Fu Z; Yang J; Zhang-Negrerie D; Gao Q
Eur J Med Chem; 2016 Mar; 110():32-42. PubMed ID: 26807543
[TBL] [Abstract][Full Text] [Related]
40. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
Rice JR; Gerberich JL; Nowotnik DP; Howell SB
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
